Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408104 · ClinicalTrials.gov registry record
Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 28
- Enrollment target
NCT05408104: Completed study, sponsored by University of Chicago.
NCT05408104 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05408104 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
This research study will compare two standard of care approaches for managing low sodium levels in heart failure patients with Left Ventricular Assist Device (LVAD). The study will compare the outcomes of LVAD patients with low sodium levels who take Tolvaptan to those who do not take Tolvaptan. Tolvaptan is FDA approved for use in the study population and is commonly used to treat low sodium levels in heart failure and LVAD patients. It is not known if taking Tolvaptan or not taking Tolvaptan is better at improving outcomes in newly implanted LVAD patients with low sodium levels. By doing this study, the Principal Investigator (PI) hopes to learn which is better at improving outcomes.
Interventions
- DRUG tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2022-05-01 |
What the finished NCT05408104 record still lists
NCT05408104 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which tolvaptan is the first listed.
NCT05408104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05408104 about?
NCT05408104 is a clinical study titled "Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients". This research study will compare two standard of care approaches for managing low sodium levels in heart failure patients with Left Ventricular Assist Device (LVAD). The study will compare the outcomes of LVAD patients with low sodium levels who take Tolvaptan to those who do not take Tolvaptan. Tol...
What is the current status of trial NCT05408104?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-03-28. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT05408104?
The interventions under investigation include: tolvaptan (DRUG).
Who is sponsoring clinical trial NCT05408104?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI